drugset / Trial / NCT03932409
Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this single arm, open label study is to evaluate the feasibility of pembrolizumab combined with radiation administered to the upper part of the vagina (vaginal cuff brachytherapy) followed by three cycles of pembrolizumab and chemotherapy in patients with endometrial cancer.
Timeline
- Start
- 2020-02-19
- Primary completion
- 2025-09-25
- Completion
- 2027-06-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | Paclitaxel | Small molecule | — | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |